Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

This study is currently recruiting participants. (see Contacts and Locations)
Verified July 2014 by Memorial Sloan-Kettering Cancer Center
Sponsor:
Collaborator:
Ferring Pharmaceuticals
Information provided by (Responsible Party):
Memorial Sloan-Kettering Cancer Center
ClinicalTrials.gov Identifier:
NCT02020070
First received: December 18, 2013
Last updated: July 11, 2014
Last verified: July 2014

December 18, 2013
July 11, 2014
December 2013
December 2015   (final data collection date for primary outcome measure)
undetectable PSA [ Time Frame: at 12 and 20 months ] [ Designated as safety issue: No ]
An undetectable PSA at 12 and 20 months (weeks 52 and 84, respectively) from the start of treatment among patients with non-castrate (> 150 ng/ml) levels of testosterone. An undetectable PSA is defined as PSA ≤0.05 ng/mL.
undetectable PSA [ Time Frame: at 12 and 20 months ] [ Designated as safety issue: No ]
An undetectable PSA at 12 and 20 months from the start of treatment among patients with non-castrate (> 150 ng/ml) levels of testosterone. An undetectable PSA is defined as PSA ≤0.05 ng/mL.
Complete list of historical versions of study NCT02020070 on ClinicalTrials.gov Archive Site
  • progression-free survival (PFS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Progression-free survival (PFS) is a composite endpoint defined as disease progression in bone or soft-tissue, symptoms, or death measured from study entry. Progression in soft tissue will be measured by modified RECIST per PCWG2..
  • overall survival (OS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Overall survival is defined as death from any cause measured from study entry.
  • Toxicity [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Safety will be evaluated for all treated patients using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (http://ctep.cancer.gov). Safety assessments will be based on medical review of AE reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests.
  • progression-free survival (PFS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Progression-free survival (PFS) is a composite endpoint defined as disease progression in bone or soft-tissue, symptoms, or death measured from study entry. In addition to an undetectable PSA, any pathological lymph nodes (whether target or non target) must have reduction in short axis to <10 mm (Complete Response per RECIST) in order to meet the criteria for PFS.
  • overall survival (OS) [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Overall survival is defined as death from any cause measured from study entry.
  • Safety [ Time Frame: 2 years ] [ Designated as safety issue: Yes ]
    Safety will be evaluated for all treated patients using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), Version 4.0 (http://ctep.cancer.gov). Safety assessments will be based on medical review of AE reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests.
Not Provided
Not Provided
 
Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy
A Phase 2 Study Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

The purpose of this study is to find out what effects, good and/or bad, taking ipilimumab with degarelix before surgery to remove the prostate, followed by more degarelix and ipilimumab after the surgery, will have on prostate cancer.

The goal of this trial is to assess the safety and efficacy of a multimodality approach combining hormones and immunotherapy in prostate cancer populations that are considered incurable and standardly treated with hormones alone, and represent clinical states prior to development of castration-resistant disease. There are 2 cohorts. The first will use ipilimumab and degarelix prior to and following radical prostatectomy in men with newly diagnosed, oligometastatic, castration-sensitive disease. The second cohort will include men who have already received definitive local therapy with radical prostatectomy but have since experienced biochemical recurrence.

Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Metastatic Castration Sensitive Prostate Cancer
  • Drug: Degarelix
  • Drug: Ipilimumab
  • Procedure: Radical Prostatectomy
  • Experimental: Ipilimumab & Degarelix With Radical Prostatectomy

    Week 1: Degarelix 240 mg SQ injection and Ipilimumab at 10 mg/kg intravenously (IV). Surgery Radical prostatectomy (RP)will be performed during week 3 ± 1 week or after recovery to grade ≤ 1 adverse events experienced during the induction period related to treatment. Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ

    Week 11, 14, 17 or after sufficient wound healing and recovery post RP:

    Ipilimumab 10mg/kg IV Follow-up Twelve week intervals until Week 87.

    Interventions:
    • Drug: Degarelix
    • Drug: Ipilimumab
    • Procedure: Radical Prostatectomy
  • Experimental: Ipilimumab & Degarelix With Prior With Radical Prostatectomy
    Week 1: Degarelix 240 mg SQ injection and Ipilimumab at 3 mg/kg intravenously (IV) Continued Androgen Depletion and Ipilimumab Weeks 5, 9, 13, 17, 21, 25, and 29: Degarelix 80 mg SQ Week 4,7,10: Ipilimumab 3mg/kg IV Follow-up Twelve week intervals until Week 81, with MD visits at weeks 52 and 84 (12 and 20 months).
    Interventions:
    • Drug: Degarelix
    • Drug: Ipilimumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
53
Not Provided
December 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

Target Population: Cohort A Patients with castration-sensitive oligometastatic prostate cancer who have not received primary local therapy (radiation or surgery), and no more than 5 months of prior androgen deprivation therapy.

  • The subject must be age 18 or older, and be willing and able to provide informed consent.
  • The subject must have histologically confirmed adenocarcinoma of the prostate with tissue confirmation at selected study site.
  • The subject must have newly diagnosed prostate cancer with a metastatic site(s).
  • The subject must have ≤ 10 bony metastatic lesions detected by nuclear medicine bone scan.
  • Distant metastatic lymph node(s) (e.g., retroperitoneal or non-regional pelvic lymph nodes) are allowed
  • Regional pelvic lymph nodes (as per AJCC Cancer Staging [7th edition]) will be considered a metastatic site if greater than 1.5cm in shortest dimension.
  • The subject must have Karnofsky performance status of 80-100.
  • Normal organ function with acceptable initial laboratory values:

    • WBC ≥ 2000/μL
    • ANC ≥ 1000/ μL
    • Platelets ≥ 75 x 103/μL
    • Creatinine ≤ 2.0 x ULN
    • AST/ALT ≤ 2.5 x ULN
    • Bilirubin ≤ 1.5 x ULN (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
  • No active or chronic infection with HIV, Hepatitis B or Hepatitis C (negative screening tests required).
  • The subject must be deemed medically fit for radical prostatectomy by the attending urologic surgeon at the selected study site.
  • Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study [and for up to 26 weeks after the last dose of ipilimumab] in such a manner that the risk of pregnancy is minimized.

Exclusion Criteria:

  • Patients that meet any of the criteria listed below will not be eligible for Cohort A entry:
  • Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer or superficial bladder cancer
  • Major surgery within 4 weeks of enrollment (Week 1 Visit).
  • Current or prior radiation therapy to the prostate Prior radiation to a metastatic site (e.g., palliative radiation) is allowed..
  • More than 5 months of prior hormonal therapy (e.g., gonadotropin hormone releasing analogs, megestrol acetate, or casodex) . There is no washout period required for GnRH analogs. A two week washout is required for megestrol or anti-androgen.
  • Prior use of an 5 alpha reductase inhibitor is allowed (no limit on duration of use), however a two week washout is required.
  • Prior ketoconazole, abiraterone acetate, or enzalutamide for the treatment of prostate cancer.
  • Current or prior investigational therapies for prostate cancer, or chemotherapy administered with the intent to treat prostate cancer.
  • Concomitant therapy with any other experimental drug.
  • Autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis).
  • Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of ipilimumab hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea.
  • Patients with underlying heart conditions who are deemed ineligible for surgery.
  • Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 1 month before or after any dose of ipilimumab).
  • Note: Inactivated vaccines are allowed at any time on study.
  • A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA-4 inhibitor or agonist.
  • Concomitant or prior therapy with any of the following: IL-2, interferon, or other nonstudy immunotherapy regimens; immunosuppressive agents; ; or chronic use of systemic corticosteroids within 6 weeks of study entry.
  • Persons of reproductive potential unwilling to use an adequate method of contraception throughout treatment and for at least 26 weeks after ipilimumab is stopped.
  • Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation.

Inclusion Criteria:

Target Population: Cohort B

  • The subject must be age 18 or older, and be willing and able to provide informed consent.
  • Histologically confirmed prostate cancer with progressive disease, defined as:
  • Rising PSA (50% or more increase to a level of 1 ng/mL or more, based on at least 3 PSA determinations obtained at least 1 week apart). The 50% rise in PSA is across the 3 determinations, and these determinations do not need to be sequential.
  • PSA doubling time of ≤ 12 months as calculated according to the Memorial Sloan-Kettering Cancer Center nomogram (http://www.mskcc.org/mskcc/html/10088.cfm)
  • No radiographic evidence of distant metastatic disease (e.g., bone or visceral disease, non-regional lymph node, etc.)
  • Note: Pelvic or regional lymph nodes are allowed

    • The subject must have Karnofsky performance status of 80-100.
    • Normal organ function with acceptable initial laboratory values:
    • WBC ≥ 2000/μL
    • ANC ≥ 1000/ μL
    • Platelets ≥ 75 x 103/μL
    • Creatinine ≤ 2.0 x ULN
    • AST/ALT ≤ 2.5 x ULN
    • Bilirubin ≤ 1.5 x ULN (except patients with Gilbert's Syndrome, who must have a total bilirubin less than 3.0 mg/dL)
  • No active or chronic infection with HIV, Hepatitis B or Hepatitis C (negative screening tests required).
  • Prior radiotherapy to the prostate (adjuvant or salvage radiotherapy) is allowed
  • Men of fathering potential must be using an adequate method of contraception to avoid conception throughout the study [and for up to 26 weeks after the last dose of ipilimumab] in such a manner that the risk of pregnancy is minimized.

Exclusion Criteria:

Target Population: Cohort B

Patients that meet any of the criteria listed below will not be eligible for Cohort B entry:

  • Any other malignancy from which the patient has been disease-free for less than 5 years, with the exception of adequately treated and cured basal or squamous cell skin cancer or superficial bladder cancer
  • Major surgery within 4 weeks of enrollment (Week 1 Visit).
  • More than 3 cycles of intermittent hormones (for the treatment of biochemical recurrence), with a cycle defined as a period of consistent androgen deprivation therapy (generally 3-9 months) followed by intentional cessation of ADT without reinitiation of ADT until the PSA rises.
  • Prior use of an 5 alpha reductase inhibitor is allowed (no limit on duration of use), however a two week washout is required.
  • Prior ketoconazole, abiraterone acetate, or enzalutamide for the treatment of prostate cancer.
  • Current or prior investigational therapies for prostate cancer, or chemotherapy administered with the intent to treat prostate cancer.
  • Concomitant therapy with any other experimental drug.
  • Autoimmune disease: Patients with a history of inflammatory bowel disease, including ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [e.g., Wegener's granulomatosis]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis).
  • Any underlying medical or psychiatric condition, which in the opinion of the investigator will make the administration of ipilimumab hazardous or obscure the interpretation of AEs, such as a condition associated with frequent diarrhea.
  • Any non-oncology vaccine therapy used for prevention of infectious diseases (for up to 1 month before or after any dose of ipilimumab).
  • Note: Inactivated vaccines are allowed at any time on study.
  • A history of prior treatment with ipilimumab or prior CD137 agonist or CTLA-4 inhibitor or agonist.
  • Concomitant or prior therapy with any of the following: IL-2, interferon, or other non-study immunotherapy regimens; immunosuppressive agents; ; or chronic use of systemic corticosteroids within 6 weeks of study entry.
  • Persons of reproductive potential unwilling to use an adequate method of contraception throughout treatment and for at least 26 weeks after ipilimumab is stopped.
  • Patients who have had a history of acute diverticulitis, intra-abdominal abscess, GI obstruction and abdominal carcinomatosis which are known risk factors for bowel perforation.
Male
18 Years and older
No
Contact: Karen Autio, MD 646-422-4632
Contact: Howard Scher, MD 646-422-4330
United States
 
NCT02020070
13-134
Not Provided
Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
Ferring Pharmaceuticals
Principal Investigator: Karen Autio, MD Memorial Sloan-Kettering Cancer Center
Memorial Sloan-Kettering Cancer Center
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP